Table 1.

Blood mononuclear cell gene expression studies in human atherosclerosis

Samples	Techniques	Findings	Reference
Purified CD14+ monocytes from CEA and normal subjects	SAGE, RT-PCR	FOS was the most differentially expressed gene in patients with atherosclerosis and may mediate pathogenesis	(Patino et al. 2005)
Blood MNCs from CEA patients and controls	Microarray: Affymetrix U133A, RT-PCR	EGR1 gene was identified as the most highly expressed marker in patients	(Gui et al. 2004)
Blood MNCs from acute ischemic stroke and normal subjects	Microarray: Affymetrix U133A, RT-PCR	A panel of differentially expressed genes including FOS was able to identify stroke subjects with 78% sensititivity and 80% specificity	(Moore et al. 2005)
Blood MNCs from hyperlipidemic patients treated with atorvastatin over 4 weeks	Microarray: Affymetrix U95Av2, RT-PCR	31% of the statin responsive genes were observed at 36h, prior to any significant decrease in serum lipid levels	(Wibaut-Berlaimont et al. 2005)
Purified CD14+ monocytes from nondiabetic, well- or poorly-controlled diabetic subjects	RT-PCR	The degree of diabetic control and activated monocyte/macrophage marker gene expression were found to be correlated	(Cipolletta et al. 2005)
The CardioGene Study: blood MNCs from 350 consecutive patients undergoing coronary artery stent placement	Microarray: Affymetrix U133A	One of the genomic components of this multicenter study examines the relationship between MNC gene expression at pre-stent, 2 weeks and 6 months after stent placement and restenosis at 6 and 12 months	(Ganesh et al. 2004)

Abbreviations: MNCs, mononuclear cells; RT-PCR, real-time polymerase chain reaction; CEA, carotid endarterectomy; FOS, Finkel-Biskis-Jinkins osteosarcoma; EGR1, early growth response gene 1